Insulet Corporation (PODD)
NASDAQ: PODDHealth CareMedical/Dental InstrumentsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
PODD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $9.32B
- P/E (TTM)
- 25.21
- Forward P/E
- 17.38
- EPS (TTM)
- $5.33
- Dividend yield
- None
- 52-week range
- 126.40 – 354.88
- Day range
- 133.33 – 137.01
- Volume / Avg
- 988.48K / 1.69M
- Beta
- —
- Shares outstanding
- 69.35M
- Next earnings
- Nov 4, 2026
52-week range
PODD stock today
Shares of Insulet (PODD) finished lower on Oct 7 at $134.36, a drop of 0.27% or $0.37 per share, versus the S&P 500's 0.22% decline. Shares are 62.1% below their 52-week high of $354.88, set on Nov 20, 2025 and 6.3% above the 52-week low of $126.40, near the bottom of the past year's range. PODD is down 52.7% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 57.1%.
At 25.2x trailing earnings, Insulet trades below the peer-group median of 34.9x. Its forward P/E of 17.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Insulet's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Insulet
Company profileInsulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Ms. Ashley A. McEvoy
- Headquarters
- Acton, MA
- Employees
- 5,400
- IPO year
- 2007
- Website
- insulet.com
Financial highlights
Full financialsIn fiscal 2025, Insulet generated $2.71 billion in revenue, up 30.7% from fiscal 2024, its 11th consecutive year of revenue growth. Net income was $247.1 million (-40.9% year over year), for a net margin of 9.1% versus a median of 1.5% in the prior 5 years. Gross margin was 71.6% (up from 69.8%) and operating margin 17.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.71B | $2.07B | $1.70B | $1.31B | $1.10B |
| Growth | +30.73% | +22.07% | +30.02% | +18.79% | +21.49% |
| Net income | $247.10M | $418.30M | $206.30M | $4.60M | $16.80M |
| EPS (diluted) | $3.48 | $5.78 | $2.94 | $0.07 | $0.24 |
Analyst forecast
ForecastConsensus (26 analysts)
buy
Avg. price target
$170.96+27.24%
- Strong buy 4
- Buy 11
- Hold 11
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $1.59
- Last reported (Q2 2026)
- Aug 5, 2026
- EPS actual vs est.
- $1.37 vs —
PODD news
All PODD newsInsulet peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GMEDGlobus Medical Inc. Class A | 73.75 | -3.51% | $9.90B | vs PODD |
| GKOSGlaukos Corporation | 172.18 | +6.55% | $10.16B | vs PODD |
| BAXBaxter International Inc. | 23.97 | -1.60% | $12.39B | vs PODD |
| PENPenumbra Inc. | 316.35 | -0.22% | $12.46B | vs PODD |
| MMEDMiniMed Group Inc. | 19.11 | -2.70% | $5.38B | vs PODD |
| STVNStevanato Group S.p.A. | 19.44 | -2.11% | $5.31B | vs PODD |
| TFXTeleflex Incorporated | 124.48 | -0.21% | $5.27B | vs PODD |
| MMSIMerit Medical Systems Inc. | 85.09 | +0.15% | $5.08B | vs PODD |
Indexes, lists and sector
Index membership
Insulet stock FAQ
What is Insulet's stock price today?
PODD last traded at $134.36 as of Oct 7, 4:00 PM EDT, down 0.27% on the day. Prices are delayed at least 15 minutes.
When is Insulet's next earnings date?
Insulet is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $1.59.
What is PODD's P/E ratio?
PODD trades at a trailing P/E ratio of 25.21 and a forward P/E of 17.38, compared with a median of 34.9 for its closest peers.
Is Insulet in the S&P 500?
Yes. Insulet (PODD) is a constituent of the S&P 500 index.
Who is Insulet's CEO?
Ms. Ashley A. McEvoy is the chief executive officer of Insulet Corporation, which has about 5,400 employees.
What is the PODD 52-week high?
The 52-week high for PODD is $354.88 and the 52-week low is $126.40. The stock is currently 62.1% below its high.